Great article, and it highlights how undervalued IHL is with 6 development programs underway and potentially a second psychedelics program as well. All the value is created by IP, that’s crystal clear and progressing rapidly.
GW Pharma has been acquired by NASDAQ listed Jazz Pharma for US$7.2 billion (A$9 billion). They have one flagship CBD drug, Epidiolex which we’ve discussed on this thread.
MindMed is now US$1.4 billion (A$1.8 billion) with a psychedelics program.
What could IHL could be valued at on the NASDAQ?
General discussion, page-5393
-
- There are more pages in this discussion • 14,605 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)